Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Allergy Diagnostics Market Size & Share 2026-2035
Report ID: GMI5621
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Allergy Diagnostics Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Allergy Diagnostics Market Size
The allergy diagnostics market generated USD 6 billion in revenue in 2025, rising to USD 6.54 billion in 2026 and expanding at a 9.3% CAGR (2026-2035) to reach USD 14.61 billion by 2035.
Allergy Diagnostics Market Key Takeaways
Market Leader: Thermo Fisher Scientific led with over 14.7% market share in 2025.
Leading Players: Top 5 players in this market include Thermo Fisher Scientific, Siemens Healthineers, Revvity, Stallergenes Greer, HollisterStier Allergy, which collectively held a market share of 23.3% in 2025.
The allergy diagnostics market is moving toward laboratory-confirmed sensitization assessment as clinicians seek greater specificity in respiratory, food, drug, and venom allergy workups. Demand is increasingly shaped by the installed base of immunoassay platforms, recurring reagent requirements, and adoption of component-resolved approaches that can inform more targeted clinical management.
GMI Analyst View
Based on primary research engagements and bottom-up triangulation conducted by GMI's analyst team, approximately 138 million allergy diagnostic tests were administered globally in 2025, reflecting a critical mass of IgE-driven demand that positions the market for continued structural volume growth through the forecast period. This aggregate testing volume also highlights persistent underdiagnosis in lower-income markets and reinforces the durable consumable cycle embedded in higher-reimbursement settings.
Allergy Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
Allergy diagnostics demand is shifting toward higher-specificity in vitro testing, broader allergen panels, and workflows that connect diagnostic results to treatment selection. The outlook depends on whether healthcare systems can widen testing access while laboratories manage reimbursement pressure, assay regulation, and the operational economics of specialized testing.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The allergy disease burden broadens the clinical population for diagnostic assessment, particularly where respiratory symptoms, food reactions, and polysensitization require differentiation before therapy is selected. For laboratories, this creates recurring demand after platform placement because each diagnostic episode consumes proprietary reagents, controls, or panel materials. The commercial opportunity is therefore tied not only to patient presentation, but also to the ability of providers to integrate allergy testing into repeatable referral and follow-up pathways.
Food allergy management increasingly requires clinicians to distinguish clinically consequential sensitization from cross-reactivity. That distinction favors component-resolved testing in specialty settings, where molecular detail can support counseling, dietary guidance, and immunotherapy decisions. As allergy centers adopt more protocolized workups, the mix of testing is likely to move toward assays that deliver a more differentiated clinical result rather than the lowest-cost screening option.
Multiplex platforms address an operational constraint in patients with complex sensitization histories: the need to obtain broad immunological information without a long sequence of separate tests. Their value proposition is strongest in reference laboratories and specialist centers managing high volumes of multi-allergen workups, where the ability to consolidate testing can improve workflow utilization and support the migration from broad extract-based assessment to more specific molecular panels.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Testing affordability can restrict utilization even where allergy awareness is high. When a diagnostic episode requires specialist referral, testing, follow-up consultation, and potentially confirmatory work, patients may defer evaluation or clinicians may reserve testing for more severe presentations. The result is a meaningful gap between the population with symptoms suggestive of allergy and the population entering a formal diagnostic pathway.
The access challenge is particularly material in lower-income populations and emerging healthcare systems, where reimbursement design and laboratory availability can determine whether patients receive preventive testing or only seek care after an acute event. This creates an addressable-market constraint for suppliers: clinical need may be substantial, while effective demand remains concentrated in well-funded private laboratories, hospital networks, and urban specialty centers.
Regulatory change also affects the competitive supply of allergy assays. Manufacturers with established clinical-evidence programs and quality systems are better positioned to sustain broad menus through certification cycles, while smaller suppliers may face longer commercialization timelines. This can reinforce the importance of portfolio breadth, regulatory execution, and established laboratory relationships among leading platform providers.
GMI Analyst View
We see the most durable growth coming from the convergence of clinical specificity and laboratory economics. Suppliers that combine broad component menus with efficient automation are better placed to capture the shift from episodic screening to protocol-driven allergy management, while testing formats that remain difficult to reimburse will face a narrower path to scaled adoption.
Allergy Diagnostics Market Segment Analysis
By Product & Service
Instruments
Instruments generated USD 1.50 billion in revenue in 2025 and are projected to expand at an 8.0% CAGR (2026-2035). Demand is anchored in automated IgE analyzers, immunoassay platforms, and skin-testing devices, with new placements increasingly concentrated in hospital and reference-laboratory buildouts where allergy testing is incorporated into broader diagnostic workflows.
Consumables
Consumables accounted for 60.0% of global allergy diagnostics revenue in 2025 and are projected to generate USD 9.14 billion by 2035. Their prominence reflects the recurring purchase cycle associated with reagents, allergen strips, calibration materials, and test kits; component-resolved panels can further improve revenue per installed platform by shifting the product mix toward more specialized assays.
Services
Services are projected to account for 15.3% of global allergy diagnostics revenue by 2035 and expand at a 9.5% CAGR (2026-2035). Outsourced testing, specialist interpretation, and digitally connected reporting are increasingly relevant where hospitals lack in-house immunology capacity or require access to a broader panel menu than local laboratories can maintain.
By Test Type
In Vivo
In vivo testing accounted for 30.0% of global allergy diagnostics revenue in 2025 and is expected to grow at a 7.5% CAGR (2026-2035). Skin prick and intradermal methods retain an important role in allergy practices because they offer immediate clinical feedback and fit established specialist workflows, although their relative position is constrained by the growing specificity and standardization available through laboratory methods.
In Vitro
In vitro allergy diagnostics generated USD 4.20 billion in 2025 and are projected to reach USD 10.90 billion by 2035. The segment benefits from demand for quantitative allergen-specific immunological assessment, compatibility with high-throughput laboratory workflows, and the ability of multiplex and component-resolved formats to provide molecular detail that skin-based testing may not deliver.
By Allergen Type
Inhaled Allergens
Inhaled aeroallergen diagnostics represented 45.0% of global allergy diagnostics revenue in 2025 and are expected to grow at an 8.3% CAGR (2026-2035). Respiratory conditions remain the highest-volume testing use case because pollen, dust mite, pet dander, mold, and other inhalant exposures are embedded in routine allergy and respiratory care pathways.
Food Allergens
Food allergen testing generated USD 2.10 billion in 2025 and is projected to account for 40.2% of global allergy diagnostics revenue by 2035. The segment is gaining strategic importance as pediatric food-allergy workups increasingly rely on component-level information to distinguish clinically relevant sensitization patterns from cross-reactive findings and support individualized risk management.
Drug Allergens
Drug allergen diagnostics represented 12.0% of global allergy diagnostics revenue in 2025 and are projected to generate USD 1.67 billion by 2035. Demand is supported by the complexity of evaluating hypersensitivity to antibiotics, anti-inflammatory medicines, contrast agents, and biologics, particularly where provocation testing is unsuitable and specialized laboratory methods can serve as useful adjuncts.
Other Allergens
Other allergen categories generated USD 480 million in 2025 and are projected to account for 7.3% of global allergy diagnostics revenue by 2035. Venom, latex, mold, and occupational allergen testing remains clinically important in specialist and workplace-health settings, where exposure history and treatment eligibility can require a more focused diagnostic pathway.
By End Use
Hospital-Based Labs
Hospital-based laboratories generated USD 2.70 billion in revenue in 2025 and are expected to grow at an 8.8% CAGR (2026-2035). Their role is reinforced by direct access to allergy, immunology, respiratory, and pediatric specialists, allowing testing results to be incorporated into diagnostic workups and treatment planning within the same care network.
Diagnostic Labs
Diagnostic laboratories accounted for 40.0% of global allergy diagnostics revenue in 2025 and are projected to generate USD 5.92 billion by 2035. These providers aggregate referrals from clinics that lack in-house immunoassay capacity and can support a wider menu of component-resolved and multiplex testing than many individual hospital laboratories.
Other End Use
Other end-use settings are projected to generate USD 2.43 billion by 2035 and expand at a 10.5% CAGR (2026-2035). Point-of-care clinics, occupational health providers, consumer-facing testing services, and research facilities broaden the market beyond traditional institutional laboratories, although clinical validation, referral pathways, and reimbursement will determine which decentralized formats achieve sustained adoption.
GMI Analyst View
We view consumables as the segment that most clearly captures the market's underlying platform economics. Instrument placements establish access, but the long-term value is realized through reagent utilization, menu expansion, and the ability to move laboratories toward higher-specificity testing formats without disrupting established workflows.
Allergy Diagnostics Market Regional Analysis
North America Allergy Diagnostics Market Analysis
The allergy diagnostics market in North America accounted for 32.0% of global revenue in 2025 and is projected to reach USD 4.03 billion by 2035. High reimbursement availability, dense specialty referral networks, and an established base of automated immunoassay platforms support demand, while the region's mature infrastructure increases the importance of assay-menu breadth and clinical differentiation.
U.S.
The U.S. generated USD 1.66 billion in allergy diagnostics revenue in 2025 and is projected to reach USD 3.38 billion by 2035. Demand is underpinned by established allergy specialty care, broad clinical use of allergen-specific IgE testing, and continued adoption of component-resolved food allergy panels in hospital, reference-laboratory, and consumer-accessed pathways.
Canada
Canada is projected to generate USD 645 million by 2035 and expand at a 9.5% CAGR (2026-2035). Provincial healthcare delivery models and growing recognition of food allergy needs create an opportunity to extend testing beyond private specialist settings, particularly as laboratory services seek to improve access to allergen-specific assessment.
Europe Allergy Diagnostics Market Analysis
Europe generated USD 1.68 billion in revenue in 2025 and is projected to account for 25.3% of global allergy diagnostics revenue by 2035. Mature allergy-care infrastructure supports in vitro testing demand, while IVDR implementation raises the strategic value of manufacturers that can maintain compliant specialty assay portfolios and support laboratories through changing regulatory requirements.
Germany
Germany accounted for 20.0% of European allergy diagnostics revenue in 2025 and is expected to grow at a 7.3% CAGR (2026-2035). Its extensive allergy specialty practice base, statutory health coverage, and active clinical research environment support the continued use of advanced in vitro and component-resolved testing protocols.
UK
The UK generated USD 302 million in revenue in 2025 and is projected to reach USD 635 million by 2035. National Health Service pathways remain central to demand, while private laboratory services can address patient demand for quicker access to broader allergy panels and more detailed food-allergy testing.
France
France is projected to account for 14.6% of European allergy diagnostics revenue by 2035 and expand at a 7.9% CAGR (2026-2035). Hospital allergy centers and reference immunology laboratories provide a stable institutional base, while urban food and respiratory allergy demand supports incremental testing utilization.
Italy
Italy generated USD 202 million in revenue in 2025 and is projected to reach USD 449 million by 2035. Respiratory and food allergy demand, together with the development of private diagnostic capacity in major urban areas, supports utilization across both routine and specialized allergen panels.
Spain
Spain is projected to generate USD 384 million by 2035 and expand at an 8.6% CAGR (2026-2035). Private diagnostics adoption and country-specific aeroallergen and food-allergen testing requirements are supporting increased use of component-resolved methods in specialist allergy settings.
Netherlands
The Netherlands accounted for 8.0% of European allergy diagnostics revenue in 2025 and is expected to grow at a 7.1% CAGR (2026-2035). Consolidated hospital laboratories and broad insurance coverage support stable demand, while academic medical centers continue to influence protocol development and diagnostic quality standards.
Rest of Europe
Rest of Europe is projected to generate USD 739 million by 2035 and grow at a 9.9% CAGR (2026-2035). Lower historical testing penetration in several Central and Eastern European markets creates scope for catch-up growth as hospital modernization, private healthcare utilization, and allergy awareness expand.
Asia Pacific Allergy Diagnostics Market Analysis
The allergy diagnostics market in Asia Pacific accounted for 28.0% of global revenue in 2025 and is projected to reach USD 4.85 billion by 2035. The region combines expanding diagnostic infrastructure in large emerging markets with sophisticated adoption of immunoassay technology in developed healthcare systems, creating distinct opportunities across volume testing and premium specialty panels.
China
China accounted for 30.0% of Asia Pacific allergy diagnostics revenue in 2025 and is projected to generate USD 1.59 billion by 2035. Reimbursement expansion, domestic IVD development, and wider placement of automated analyzers beyond top-tier hospitals are increasing access to allergy testing for respiratory and food-allergen applications.
Japan
Japan generated USD 336 million in revenue in 2025 and is projected to reach USD 743 million by 2035. Its advanced allergy practice environment supports early adoption of comprehensive panels, while recurring management of atopic comorbidities creates demand for testing across multiple points in the patient journey.
India
India is projected to generate USD 671 million by 2035 and expand at a 13.8% CAGR (2026-2035). Low formal testing penetration, expanding private laboratory networks, and broader access to specialist healthcare create an opportunity for providers that can offer affordable, scalable testing models suited to diverse urban and secondary-care environments.
South Korea
South Korea generated USD 168 million in revenue in 2025 and is expected to grow at a 9.2% CAGR (2026-2035). A technologically advanced laboratory environment, reimbursement support for IgE testing, and consumer engagement with digitally enabled healthcare are supporting demand for multiplex and connected allergy-testing formats.
Australia
Australia generated USD 134 million in revenue in 2025 and is expected to grow at a 7.3% CAGR (2026-2035). The market is comparatively mature, with demand centered on specialist-led food allergy testing and component-resolved assessment within established clinical guideline frameworks.
Rest of Asia Pacific
Rest of Asia Pacific is projected to generate USD 1.16 billion by 2035 and grow at a 12.7% CAGR (2026-2035). Growing private-hospital investment and a large underserved patient population create substantial potential, although reagent access, laboratory capability, and reimbursement progression will shape the speed of market development.
Latin America Allergy Diagnostics Market Analysis
The allergy diagnostics market in Latin America is projected to reach USD 1.16 billion by 2035 and expand at a 10.7% CAGR (2026-2035). Rising middle-class healthcare utilization and public-sector investment are improving access in leading markets, although diagnostic infrastructure and proprietary reagent availability remain uneven outside major metropolitan centers.
Brazil
Brazil generated USD 189 million in revenue in 2025 and is projected to reach USD 543 million by 2035. Public hospital laboratory expansion and growing private-sector panel menus support demand for respiratory and food-allergen testing, particularly in large urban healthcare networks.
Mexico
Mexico accounted for 30.0% of Latin America allergy diagnostics revenue in 2025 and is expected to grow at a 10.6% CAGR (2026-2035). The expansion of public insurance-supported services and private diagnostic capacity is widening access to IgE testing across allergy, respiratory, and pediatric specialty care.
Argentina
Argentina is projected to generate USD 142 million by 2035 and grow at an 8.5% CAGR (2026-2035). Macroeconomic volatility can limit equipment investment and reagent purchasing flexibility, but concentrated private healthcare networks continue to sustain specialist testing demand in major population centers.
Rest of Latin America
Rest of Latin America is projected to account for 11.3% of regional allergy diagnostics revenue by 2035 and expand at a 12.1% CAGR (2026-2035). Earlier-stage markets offer growth potential as private health-plan coverage, laboratory investment, and awareness of formal allergy diagnosis improve.
Middle East & Africa Allergy Diagnostics Market Analysis
The allergy diagnostics market in Middle East & Africa generated USD 300 million in 2025 and is projected to reach USD 867 million by 2035. Demand is shaped by a sharp contrast between well-funded Gulf healthcare systems and markets where shortages of specialist personnel, diagnostic infrastructure, and reimbursement coverage constrain testing access.
Saudi Arabia
Saudi Arabia is projected to generate USD 290 million by 2035 and grow at a 12.4% CAGR (2026-2035). Healthcare modernization and laboratory-equipment investment are strengthening the availability of allergy testing in major urban centers, with demand supported by respiratory, dust, mold, and food-allergen assessments.
UAE
The UAE is projected to account for 26.8% of Middle East & Africa allergy diagnostics revenue by 2035 and grow at an 11.9% CAGR (2026-2035). Advanced private hospital infrastructure, international patient flows, and high private healthcare spending support demand for premium IgE, component-resolved, and multiplex testing.
South Africa
South Africa generated USD 60 million in revenue in 2025 and is expected to grow at a 9.0% CAGR (2026-2035). Growth is concentrated in private hospitals and specialist practices, while constrained public-sector access limits the broader penetration of advanced allergy diagnostics.
Rest of MEA
Rest of MEA accounted for 25.0% of Middle East & Africa allergy diagnostics revenue in 2025 and is projected to generate USD 203 million by 2035. Testing remains concentrated in private laboratories and academic hospitals, but rising urban allergy burden and gradual expansion of diagnostic networks provide a foundation for longer-term market development.
GMI Analyst View
We expect regional competition to diverge sharply rather than converge. Mature markets will reward clinical evidence, menu differentiation, and laboratory integration, whereas faster-developing markets will favor suppliers that can pair accessible platform economics with reliable local distribution, service support, and reagent continuity.
Allergy Diagnostics Market Share & Competitive Landscape
The global allergy diagnostics market exhibits a fragmented competitive structure, with Thermo Fisher Scientific, Stallergenes Greer, Siemens Healthineers, Danaher Corporation (Beckman Coulter), and EUROIMMUN (Revvity) collectively accounting for approximately 23.3% of total market revenue in 2025. Competition is driven by proprietary allergen panels, assay accuracy, installed-base penetration, regulatory expertise, laboratory workflow integration, and the ability to support both routine allergen screening and advanced component-resolved diagnostics. Market participants benefit from closed-platform reagent ecosystems, recurring consumables demand, and long-term relationships with hospitals, reference laboratories, and specialty allergy clinics. As diagnostic approaches increasingly shift toward personalized allergy management, suppliers are focusing on expanding test menus, improving automation, and enhancing diagnostic precision.
AgnitioST, Excelsior Bio-System, Med Phar Enterprise, REGA BIOTECHNOLOGY, SGS TAIWAN, Omega Diagnostics, and Neogen Corporation address more specialized or geographically focused opportunities. Their roles range from in vivo testing supplies and specialty reagents to food-allergen detection and laboratory services, reinforcing the market's diverse competitive structure.
Recent Industry Developments
In December 2025, the U.S. Food and Drug Administration cleared HYCOR Biomedical's NOVEOS Specific IgE assay capture reagents for peanut, milk-protein components, and egg ovalbumin components. The clearance expands the platform's component-resolved food allergy capability for U.S. clinical laboratories. [7]U.S. Food and Drug Administration. "510(k) Substantial Equivalence Decision K252775 - NOVEOS Specific IgE (sIgE) Assay." accessdata.fda.gov
In September 2025, Siemens Healthineers expanded the 3gAllergy menu on the IMMULITE 2000 XPi System with additional component allergens for peanut, house dust mite, and wheat testing. The development strengthens its ability to address molecularly detailed food and respiratory allergy workups on an established laboratory platform. [5]Siemens Healthineers. "Siemens Healthineers Expands Peanut Testing to Help Improve Allergy Sufferers' Quality of Life; Other New Component Allergens Available, too." siemens-healthineers.com
In May 2025, Revvity announced the EUROIMMUN IDS i20 automated random-access platform for specialty testing, including allergy applications. The launch supports laboratory consolidation by enabling a single system to address multiple specialty diagnostic disciplines. [6]Revvity. "Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing." businesswire.com
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →